|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Evidence that chronic hypoxia causes reversible impairment on male fertility显示文摘瞄准:在人的精子发生的参数和他们的复原时间上评估长期的组织缺氧的效果。方法:六男健康的山缓慢艰辛地旅行 ers 的 Seminological 参数在海水平在 normoxia 被评估。在到高度的 26 天暴露以后(从 2 000 m 到 5 600 m,古代蒙古帝国旧都遗迹远征) 一样的参数再在回到海水平以后被评估。这些参数再次在 6 个月以后在 1 个月以后然后再被评估。结果:精子计数被发现在回到海水平以后立即更低(P = 0.0004 ) 并且再在一个月以后(P = 0.0008 ) 。正常层次在 6 个月以后被到达。精子的活动性(%) 不在回到海水平以后立即显示出减小(P = 0.0583 ) ,而在 1 个月以后这减小是重要的(P = 0.0066 ) 。在 6 个月以后,到 pre-hypoxic 暴露值有恢复。在回到海以后立即增加的反常或不成熟的精子(%) 铺平(P = 0.0067 ) 然后再在 1 个月以后(P = 0.0004 ) 。在 6 个月以后,到起始的值有完全的恢复。在精液的能动精子的全部的数字被发现在回到海水平以后立即更低(P = 0.0024 ) 然后再在 1 个月以后(P = 0.0021 ) 。在 6 个月以后,到 pre-hypoxic 暴露值有恢复。结论:在 6 个月在精子发生和男富饶的生理的机制显示氧供应的影响以后,长期的组织缺氧在以前的 normoxic 条件的恢复导致精子减少的一个状态和如此的 seminological 参数的正规化。 | Vittore Verratti Francesco Berardinelli Camillo Di Giulio Gerardo Bosco Marisa Cacchio Mario Pellicciotta Michele Nicolai Stefano Martinotti Raffaele Tenaglia | 2008 | Asian Journal of Andrology2008，10，4： | 21 |
| 2 | 经大网膜生物支架胰岛移植技术的探讨显示文摘目的探讨临床大网膜胰岛移植途径的效力。方法2例1型糖尿病(type 1 diabetes mellitus,T1DM)患者,顺利完成胰腺修整、胰岛提取等过程后,借助腹腔镜方式,利用可吸收血浆凝血酶为生物支架,完成大网膜胰岛移植术。结果2例患者术后恢复顺利,血糖水平控制平稳、C-肽水平较移植前显著升高,糖化血红蛋白水平较前下降。结论胰岛移植是目前有希望治疗T1DM的方法之一,我们将胰岛移植到大网膜显示经大网膜生物支架胰岛移植术为T1DM患者提供了可行性技术路径。 | 王树森 裴广辉 王金山 刘尧娟 张博雅 邹家琦 刘蕾 淮明生 张雅敏 杨涛 王智平 郑虹 Xiumin Xu Camillo Ricordi 沈中阳 | 2016 | 实用器官移植电子杂志2016，4，6： | 8 |
| 3 | Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer显示文摘AIM To study tumor response, and tolerability of arterially directed embolic therapy(ADET) with polyethylene glycol embolics loaded with irinotecan for the treatment of colorectal cancer liver metastases(CRC-LM). Secondary objectives were to monitor quality of life, time to progression and survival of patients.METHODS Patients were included in the study if they were affected by CRC-LM, refractory to systemic chemotherapy, treated with ADET using polyethylene glycol embolics, and had liver involvement < 50%. Tumor response, performance status(PS), tumor marker antigens, and quality of life(QoL) were monitored at 1, 3 and 6 mo after ADET. QoL was assessed with the Palliative Performance Scale(PPS).RESULTS We treated 50 consecutive CRC-LM patients with ADET using polyethylene glycol embolics. Their tumor response one month after ADET was: 28% of complete response(CR), 48% of partial response(PR), 8% stable disease(SD), and 16% of progression. Tumor response 3 mo after ADET was CR 24%, PR 38%, SD 19% and progression disease(PD) 19%. Tumor response 6 mo after ADET was CR 18%, PR 44%, SD 21% and PD 18%. QoL was 90% PPS at each time point. Median time to progression for patients who progressed was 2.5 mo(range 0.8-6). Median follow-up was 14 mo(0.8-25 range). ADETs were performed with no complications. Observed side effects(mild or moderate intensity) were: Pain in 32% of patients, increase of transaminase levels in 20% and fever in 14%, whereas 30% of patients did not complain any adverse event. CONCLUSION The treatment of unresectable CRC-LM with ADET using polyethylene glycol microspheres loaded with irinotecan was effective in tumor response and resulted in mild toxicity, and good QoL. | Giammaria Fiorentini Riccardo Carandina Donatella Sarti Michele Nardella Odysseas Zoras Stefano Guadagni Riccardo Inchingolo Massimiliano Nestola Alessandro Felicioli Daniel Barnes Navarro Fernando Munoz Gomez Camillo Aliberti | 2017 | World Journal of Gastrointestinal Oncology2017，9，9： | 6 |
| 4 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial显示文摘 | Jordi Bruix Jean-Luc Raoul Morris Sherman Vincenzo Mazzaferro Luigi Bolondi Antonio Craxi Peter R. Galle Armando Santoro Michel Beaugrand Angelo Sangiovanni Camillo Porta Guido Gerken Jorge A. Marrero Andrea Nadel Michael Shan Marius Moscovici Dimitris Vo | 2012 | Journal of Hepatology2012，，4： | 6 |
| 5 | Multidisciplinary approach of colorectal cancer liver metastases显示文摘Large bowel cancer is a worldwide public health challenge.More than one third of patients present an advanced stage of disease at diagnosis and the liver is the most common site of metastases.Selection criteria for early diagnosis,chemotherapy and surgery have been recently expanded.The definition of resectability remains unclear.The presence of metastases is the most significant prognostic factor.For this reason the surgical resection of hepatic metastases is the leading treatment.The most appropriate resection approach remains to be defined.The two step and simultaneous resection processes of both primary and metastases have comparable survival long-term outcomes.The advent of targeted biological chemotherapeutic agents and the development of loco-regional therapies(chemoembolization,thermal ablation,arterial infusion chemotherapy) contribute to extend favorable results.Standardized evidence-based protocols are missing,hence optimal management of hepatic metastases should be single patient tailored and decided by a multidisciplinary team.This article reviews the outcomes of resection,systemic and loco-regional therapies of liver metastases originating from large bowel cancer. | Giammaria Fiorentini Donatella Sarti Camillo Aliberti Riccardo Carandina Andrea Mambrini Stefano Guadagni | 2017 | World Journal of Clinical Oncology2017，8，3： | 4 |
| 6 | 带小直径纵筋并外包CFRP的RC圆墩抗震性能研究显示文摘桥梁震害调查显示,钢筋混凝土(RC)桥墩易受损,影响震后救援和灾后重建。采用小直径纵筋替换受损纵筋并外包碳纤维布(CFRP)的技术修复受损桥墩可缩短震后修复周期,节省重建费用。以某不规则连续梁桥的RC圆墩为工程背景,选择小直径纵筋的长度和直径、外包CFRP层数为参数,开展7根缩尺比例为1∶6的RC圆墩试件的拟静力试验;选用OpenSees建立有限元模型,采用试验结果验证其准确性,并开展参数分析。研究结果表明:设置小直径纵筋的桥墩的塑性变形集中在小直径纵筋高度范围内,桥墩破坏被限制在塑性铰区域内;与未设置小直径纵筋的桥墩相比,小直径纵筋使桥墩承载力降低20%~27%,但桥墩位移延性提高42%~85%,曲率延性提高47%~242%,耗能性能提高32%~56%;在满足桥墩承载力设计要求的情况下,使用小直径纵筋可有效提高桥墩抗震性能;设置小直径纵筋的桥墩在小直径纵筋区域内的实测CFRP最大应变明显大于未设置的试件,说明对设置小直径纵筋的桥墩外包CFRP,可防止桥墩过早破坏,提高延性;随着小直径纵筋长度增大或直径减小,桥墩耗能性能先增大后减小;建议以钢筋疲劳寿命需求为下限,塑性铰长度为上限选择小直径纵筋长度;选择满足保证塑性铰以外的纵筋受力始终在弹性范围内的条件下的最大直径为小直径纵筋直径;增大修复区域的混凝土强度可弥补设置小直径纵筋造成的桥墩承载力降低。 | 薛俊青 DAVIDE Lavorato 聂尚杰 陈俊臻 BRISEGHELLA Bruno NUTI Camillo | 2022 | 中国公路学报2022，35，2： | 4 |
| 7 | Review of anticancer mechanisms of isoquercitin显示文摘This review was based on a literature search of PubM ed and Scielo databases using the keywords 'quercetin,rutin,isoquercitrin,isoquercitin(IQ),quercetin-3-glucoside,bioavailability,flavonols and favonoids,and cancer' and combinations of all the words.We collected relevant scientific publications from 1990 to 2015 about the absorption,bioavailability,chemoprevention activity,and treatment effects as well as the underlying anticancer mechanisms of isoquercitin.Flavonoids are a group of polyphenolic compounds widely distributed throughout the plant kingdom.The subclass of flavonols receives special attention owing to their health benefits.The main components of this class are quercetin,rutin,and IQ,which is a flavonoid and although mostly found as a glycoside,is an aglycone(lacks a glycoside side chain).This compound presents similar therapeutic profiles to quercetin but with superior bioavailability,resulting in increased efficacy compared to the aglycone form.IQ has therapeutic applications owing to its wide range of pharmacological effects including antioxidant,antiproliferative,anti-inflammatory,anti-hypertensive,and anti-diabetic.The protective effects of IQ in cancer may be due to actions on lipid peroxidation.In addition,the antitumor effect of IQ and its underlying mechanism are related to interactions with Wnt signaling pathway,mixed-lineage protein kinase 3,mitogen-activated protein kinase,apoptotic pathways,as well proinflammatory protein signaling.This review contributed to clarifying the mechanisms of absorption,metabolism,and actions of IQ and isoquercitrin in cancer. | Guilherme di Camillo Orfali Ana Carolina Duarte Vivien Bonadio Natalia Peres Martinez Maria Elisa Melo Branco de Araújo Fernanda Bruschi Marinho Priviero Patricia Oliveira Carvalho Denise Gon?alves Priolli | 2016 | World Journal of Clinical Oncology2016，7，2： | 4 |
| 8 | Gastric metastasis by lung small cell carcinoma显示文摘胃肠道的转移瘤是稀罕的。我们由于主要的肺癌症描述胃的转移的一个案例,由上面的胃肠的内视镜检查法(UGIE ) 揭示了。到胃的造血的转移是一个稀罕事件。到我们的知识,仅仅 55 个案例在国际文学被描述了。在这些病人,预后是很差的。我们此处由肺报导胃的转移的一个案例小房间癌,与关于这个稀罕实体的文学的评论。 | Giovanni Casella Camillo Di Bella Antonino Roberto Cambareri Carmelo Antonio Buda Gianluigi Corti Filippo Magri Stefano Crippa Vittorio Baldini | 2006 | World Journal of Gastroenterology2006，12，25： | 3 |
| 9 | Present and future cell therapies for pancreatic beta cell replenishment显示文摘If only at a small scale,islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy:the functional replenishment of damaged tissue in patients.After years of less-thanoptimal approaches to immunosuppression,recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation.Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention.Progress in stem cell research over the past decade,coupled with our decades-long experience with islet transplantation,is shaping the future of cell therapies for the treatment of diabetes.Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration,including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell lineage and the direct reprogramming of non-endocrine tissues into insulin-producing cells. | Juan Domínguez-Bendala Camillo Ricordi | 2012 | World Journal of Gastroenterology2012，18，47： | 3 |
| 10 | Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib显示文摘Even though Sorafenib has radically changed the natural history of those hepatocellular carcinoma patients who are not amenable for curative treatments, further therapeutic improvements are badly needed. As it was for Sorafenib, our increasingly refined understanding of the complex mechanisms underlying HCC carcinogenesis are the starting point for the future development of such treatments. Presently, a number of molecularly targeted agents are in different stages of development for this once orphan cancer. Indeed, several pathways are presently being explored to identify potentially active drugs, including epidermal growth factor receptor, vascular endothelial growth factor/vascular endothelial growth factor receptors, mammalian target of rapamycin, phosphatidyl-inositol-3-kinase/Akt, insulin growth factor, Aurora kinase, Wnt/β-catenin, retinoic acid receptor and hepatocyte growth factor/C-Met. This review is aimed at addressing the results obtained so far with these newer drugs, also considering the challenges we shall face in the near future, including the issue of response evaluation and identification of predictive/ prognostic biomarkers. | Camillo Porta Chiara Paglino | 2010 | World Journal of Hepatology2010，2，3： | 3 |
| 11 | Hydrogen breath test for the diagnosis of lactose intolerance,is the routine sugar load the best one?显示文摘AIM: To evaluate the prevalence of lactose intolerance (LI) following a load of 12.5 g in patients diagnosed as high-grade malabsorbers using the hydrogen breath test (HBT)-25.METHODS: Ninety patients showing high-grade malabsorption at HBT-25 were submitted to a second HBT with a lactose load of 12.5 g.Peak hydrogen production,area under the curve of hydrogen excretion and occurrence of symptoms were recorded.RESULTS: Only 16 patients (17.77%) with positive HBT-25 proved positive at HBT-12.5.Hydrogen production was lower as compared to HBT-25 (peak value 21.55 parts per million (ppm) ± 29.54 SD vs 99.43 ppm ± 40.01 SD; P < 0.001).Symptoms were present in only 13 patients.The absence of symptoms during the high-dose test has a high negative predictive value (0.84) for a negative low-dose test.The presence of symptoms during the first test was not useful for predicting a positive low-dose test (positive predictive value 0.06-0.31).CONCLUSION: Most patients with a positive HBT-25 normally absorb a lower dose of lactose and a strict lactose restriction on the basis of a 'standard' HBT is,in most instances,unnecessary.Thus,the 25 g lactose tolerance test should probably be substituted by the 12.5 g test in the diagnosis of LI,and in providing dietary guidelines to patients with suspected lactose malabsorption/intolerance. | Fiorenza Argnani Mauro Di Camillo Vanessa Marinaro Tiziana Foglietta Veronica Avallone Carlo Cannella Piero Vernia | 2008 | World Journal of Gastroenterology2008，14，40： | 3 |
| 12 | Headache, anxiety and depressive disorders: the HADAS study显示文摘 | Ettore Beghi Gennaro Bussone Domenico D’Amico Pietro Cortelli Sabina Cevoli Gian Camillo Manzoni Paola Torelli Maria Clara Tonini Giovanni Allais Roberto Simone Florindo D’Onofrio Sergio Genco Franca Moschiano Massimiliano Beghi Sara Salvi | 2010 | The Journal of Headache and Pain2010，，2： | 3 |
| 13 | Cognitive impairment in chronic obstructive pulmonary disease显示文摘 | Raffaele Antonelli Incalzi Camillo Marra Alessandro Giordano Maria Lucia Calcagni Antonella Cappa Salvatore Basso Gabriella Pagliari Leonello Fuso | 2003 | Journal of Neurology2003，，3： | 2 |
| 14 | Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases显示文摘 | Carmela Loguercio Alessandro Federico Concetta Tuccillo Fulvia Terracciano Mauro Valeriano D?Auria Claudio De Simone Camillo Del Vecchio Blanco | 2005 | Journal of Clinical Gastroenterology2005，，6： | 2 |
| 15 | Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis显示文摘 | Francesco Montagnani Gina Turrisi Claudio Marinozzi Camillo Aliberti Giammaria Fiorentini | 2011 | Gastric Cancer2011，，1： | 2 |
| 16 | Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases显示文摘 | Carmela Loguercio Alessandro Federico Concetta Tuccillo Fulvia Terracciano Mauro Valeriano D?Auria Claudio De Simone Camillo Del Vecchio Blanco | 2005 | Journal of Clinical Gastroenterology2005，，6： | 2 |
| 17 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial显示文摘 | Robert J Motzer Bernard Escudier Stéphane Oudard Thomas E Hutson Camillo Porta Sergio Bracarda Viktor Grünwald John A Thompson Robert A Figlin Norbert Hollaender Gladys Urbanowitz William J Berg Andrea Kay David Lebwohl Alain Ravaud | 2008 | The Lancet2008，，9637： | 2 |
| 18 | Lymph Node Recovery from Colorectal Tumor Specimens:Recommendation for a Minimum Number of Lymph Nodes to be Examined显示文摘 | Fabio Cianchi Annarita Palomba Vieri Boddi Luca Messerini Filippo Pucciani Giuliano Perigli Paolo Bechi Camillo Cortesini | 2002 | World Journal of Surgery2002，，3： | 2 |
| 19 | Laser-assist during extraction of chronically implanted pacemaker and defibrillator leads显示文摘 | Moon MR Camillo CJ Gleva MJ | 2002 | Ann Thorac Surg2002，73，： | 1 |
| 20 | Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers显示文摘 | Maria Morganti Monica Ciantelli Beatrice Giglioni Anna L. Putignano Stefania Nobili Laura Papi Ida Landini Cristina Napoli Rosa Valanzano Fabio Cianchi Vieri Boddi Francesco Tonelli Camillo Cortesini Teresita Mazzei Maurizio Genuardi Enrico Mini | 2005 | European Journal of Cancer2005，，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员